1.
Open Forum Infect Dis
; 11(6): ofae103, 2024 Jun.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38887478
RESUMEN
Combination antifungal therapy for invasive mucormycosis remains controversial and is inconsistently defined in prior studies. In a cohort of patients with immunocompromised status and invasive mucormycosis, we found no difference in 6-week mortality with up-front or salvage combination therapy as compared with monotherapy.